Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Leslie L. Sharp, Cathy Chang, Gerhard Frey, Jing Wang, Haizhen Liu, Charles Xing, Safak Yalcin, Marlena Walls, Yong Ben, William J. Boyle and Jay M. Short
Title Anti-tumor efficacy of BA3011, a novel Conditionally Active Biologic (CAB) anti-AXL-ADC
Journal
Vol
Issue
Date
URL https://cancerres.aacrjournals.org/content/78/13_Supplement/827
Abstract Text Cancer Res 2018;78(13 Suppl):Abstract nr 827

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
CAB-AXL-ADC BA3011 CAB-AXL-ADC is an antibody-drug conjugate comprising a reversible Axl antibody conjugated to monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to Axl-expressing tumor cells, potentially inducing cytotoxicity and tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 827; Journal of Clinical Oncology 2018 36:15_suppl, TPS12126).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown prostate cancer not applicable CAB-AXL-ADC Preclinical - Cell line xenograft Actionable In a preclinical study, CAB-AXL-ADC treatment inhibited tumor growth in a prostate cancer cell line xenograft model (Cancer Res 2018;78(13 Suppl):Abstract nr 827). detail...
Unknown unknown pancreatic cancer not applicable CAB-AXL-ADC Preclinical - Pdx Actionable In a preclinical study, CAB-AXL-ADC treatment inhibited tumor growth in a prostate cancer cell line xenograft model and in Gemzar (gemcitabine)-resistant patient-derived xenograft (PDX) models of pancreatic cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 827). detail...
Unknown unknown lung cancer not applicable CAB-AXL-ADC Preclinical - Cell line xenograft Actionable In a preclinical study, CAB-AXL-ADC treatment inhibited tumor growth in a lung cancer cell line xenograft model (Cancer Res 2018;78(13 Suppl):Abstract nr 827). detail...